Groowe Groowe / Newsroom / NMRA
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

NMRA News

Neumora Therapeutics, Inc. Common Stock

Neumora Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on Monday, March 30, 2026

globenewswire.com
NMRA

LB Pharmaceuticals Appoints R&D Biotech Executive Robert Lenz, M.D., Ph.D. to Board of Directors

globenewswire.com
LBRX NMRA AMGN ABT

LB Pharmaceuticals Appoints R&D Biotech Executive Robert Lenz, M.D., Ph.D. to Board of Directors

globenewswire.com
LBRX NMRA AMGN ABT

Neumora Therapeutics to Participate in Guggenheim Emerging Outlook: Biotech Summit 2026

globenewswire.com
NMRA

INVESTOR ALERT AND NOTICE: Kaskela Law Firm Announces Investigation of Neumora Therapeutics, Inc. (NASDAQ:NMRA) and Encourages Long-Term Neumora Investors With Losses to Contact The Firm

accessnewswire.com
NMRA

Catalyst Monitor Report: Q1 2026 Outlook: Regulatory Approvals and Late-Stage Trials Signal Strong Pipeline Momentum Across Key Therapeutic Areas

globenewswire.com
GSK RGNX OMER XENE NMRA

Neumora Therapeutics Highlights 2026 Pipeline Strategy and Anticipated Upcoming Milestones

globenewswire.com
NMRA

Neumora Therapeutics Announces Positive Results from NMRA-511 Phase 1b Signal-Seeking Study in Alzheimer’s Disease Agitation

globenewswire.com
NMRA

Neumora Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update

globenewswire.com
NMRA

Neumora Therapeutics to Participate in Upcoming Conferences in November

globenewswire.com
NMRA